Adial Pharmaceuticals ADILW 深 滬
已收盤 07-27 16:00:00 美东时间
0.0009
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0009
- 總市值 1.58万
- 52周最高 0.199
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.0004
- 委 比 0.00%
- 總股本 1750.35万
- 歷史最高 2.45
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adial Pharmaceuticals Announces 1-For-25 Reverse Stock Split, Effective Feb. 5
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,
02-04 05:23
Adial Pharmaceuticals Announces 1-for-25 Reverse Stock Split
Adial Pharmaceuticals Announces 1-for-25 Reverse Stock Split Adial Pharmaceuticals Inc. has announced a 1-for-25 reverse stock split of its common stock, effective February 5, 2026. The company's shares will continue to trade on the Nasdaq Capital Market under the symbol "ADIL" on a split-adjusted b
02-04 05:07
Adial Pharmaceuticals Publishes International Patent Application For AD04 Serotonin-3 Receptor Antagonist Therapeutic Agent To Treat Alcohol Use Disorder
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,
01-14 22:03
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
Adial Pharmaceuticals announced the publication of an international patent application for AD04, its investigational therapy for Alcohol Use Disorder (AUD) in heavy drinkers. The patent, if granted, will protect the company's core assets through at least 2025. AD04, a genetically targeted serotonin-3 receptor antagonist, has shown promising results in reducing drinking and is believed to have potential for treating other addictive disorders. The ...
01-14 14:00
Adial Pharmaceuticals announces immediate resignation of board director
Adial Pharmaceuticals ( ($ADIL) ) has issued an update. On January 5, 2025, Adi...
01-07 05:50
Adial Pharmaceuticals Secures $2.86M As Investor Exercises 9.2M Warrants At $0.31; Company To Issue 13.8M New Series F Warrants At Same Price
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today
2025-11-26 21:04
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals provided a business update and financial results for Q3 2025, highlighting progress on AD04, a Phase 3 drug for Alcohol Use Disorder (AUD). Key milestones include a successful End of Phase 2 meeting with the FDA, advancing toward Phase 3 development, and partnerships with Genomind for precision medicine testing. AD04 targets biomarker-positive AG+ patients, identified via a genetic test. The company's cash reserves were $4.6...
2025-11-14 13:30
Adial Pharma Completes Analytical Validation Of Cheek Swab Collection Method For Testing Patients For Both Clinical Trial Usage As Well As Future Commercial Application
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today
2025-10-09 20:40
Maxim Group Upgrades Adial Pharmaceuticals to Buy, Announces $1.5 Price Target
Maxim Group analyst Jason McCarthy upgrades Adial Pharmaceuticals (NASDAQ:ADIL) from Hold to Buy and announces $1.5 price target.
2025-09-30 20:32
Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder
Adial Pharmaceuticals received FDA backing for its Phase 3 AD04 trial, including endpoints and strategies for targeted populations in Alcohol Use Disorder treatment.
2025-09-16 20:03
